Clinical trials: sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.
- Trial name
- NCT00805454
- Testing
- OPC-34712
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission
This dose comparison study, taking place at over 200 sites worldwide, will compare the dosing, safety and efficacy of an investigational medicine OPC-6535 to the dosing, safety and efficacy of Asacol ® in the maintenance of…
- Trial name
- NCT00092508
- Testing
- OPC-6535, Asacol®
- Where
- 26 sites in United States
- Volunteers
- 1,725 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Congestive Heart Failure
Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
- Trial name
- NCT00043771
- Testing
- Tolvaptan
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Congestive Heart Failure
Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients
The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)
- Trial name
- NCT00043758
- Testing
- Tolvaptan
- Where
- 40 sites in United States, Canada
- Volunteers
- 170 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.